Has the recently published SELECT trial of adjuvant erlotinib in early stage EGFR-mutant NSCLC impacted your management of these patients?
SELECT trial
Community PollStarted
Do you add adjuvant EGFR TKI in resected NSCLC patients with EGFR mutations?
106 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of Colorado Cancer Center
Answered on
The SELECT trial was a well conducted single arm trial of post-operative adjuvant erlotinib in early stage patients with NSCLC bearing an activating EGFR mutation. Compared with historical controls with and without EGFR mutations, the disease free and overall survival were superior. The study establ...
Join for free or sign in to see the full answer